Phenomic and Boehringer Ingelheim Entered into a Collaboration & License Agreement to Develop Therapies Targeting Stroma-Rich Cancers
Shots:
- Phenomic announces collaboration & licensing agreement with Boehringer Ingelheim to discover targets crucial in stroma-rich cancers
- Under the agreement, Phenomic is eligible to receive up front & near-term payments of ~$9M incl. research funding & collaboration milestones, with more than $500M in Licensing fees, along with milestones, & royalties on future sales
- BI can license Phenomic's discovered cancer targets, handling all development & commercialization. By utilizing Phenomic's scTx® single-cell transcriptomics technology, the partnership seeks to develop novel therapeutic approaches, with a focus on challenging cancers where tumor stroma poses significant obstacles
Ref: Businesswire | Image: Boehringer
Related News:- Boehringer Ingelheim’s Senvelgo Received the EC Approval in Europe for the Treatment of Feline Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
